Skin cancer rates rocket 45% in 10 years
admin 29th July 2019 Uncategorised 0Rates have increased by more than a third (35%) for women and by almost three-fifths (55%) for men. More: Skin cancer rates rocket 45% in 10 years Source: News
read more
Rates have increased by more than a third (35%) for women and by almost three-fifths (55%) for men. More: Skin cancer rates rocket 45% in 10 years Source: News
read moreFor Pfizer’s blockbuster immunology drug Xeljanz, an FDA safety communication has now turned into a boxed warning. And forget the drug’s approval as a first-line ulcerative colitis treatment, at least for now. More: Red flag upgrade for Pfizer: FDA limits
read moreAbbVie is suffering from Humira biosimilar competition in Europe, but new launches in psoriasis and rheumatoid arthritis could help the drugmaker backfill losses from its top drug. Skyrizi’s latest sales figures show how. More: AbbVie's psoriasis launch Skyrizi hitting stride
read moreWith competitors racking up new indications and data wins, AstraZeneca’s Lynparza is looking to keep its lead in the PARP inhibitor field. England’s cost watchdog delivered a leg up Friday with a new recommendation—a couple caveats notwithstanding. More: AstraZeneca's Lynparza
read moreSVB Leerink analysts have a number of concerns about Vertex’s plan to hand the CEO job to Reshma Kewalramani, not the least of which is whether she has the chops to invest in R&D projects that are likely to pay
read moreOutcome Health may have settled with investors and revamped its entire organization amid allegations that it misled clients and financial backers—but it may still be too early to call it a page turned. More: FBI targeted Outcome Health and its
read more© 1994 - 2026 B.M. Pharmaceuticals